Payment overview · 2025
General Payments
$2,133.90
76 reported records · 16 companies
Healthcare provider profile · identity verified
Peter Wong, RPAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BRONX, NY · NPI 1942416284
Verified facts
What the public records show
CMS Open Payments records show Peter Wong, RPAC received $2,133.90 in general payments during 2025 across 76 reported records.
Gilead Sciences, Inc. accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Nexletol, Prolia, Shingrix, Trelegy Ellipta, Vemlidy, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 311 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synjardy by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Nexletol by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $478.83 | 22.4% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $310.19 | 14.5% | 15 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $247.98 | 11.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $226.29 | 10.6% | 10 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $195.26 | 9.2% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.09 | 5.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $93.36 | 4.4% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $87.58 | 4.1% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.56 | 3.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.03 | 3.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.98 | 3.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.54 | 2.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.27 | 2.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.73 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.36 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.85 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,133.90 | 76 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $247.98 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $195.26 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $154.35 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $142.59 | 6 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $124.09 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $109.94 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $93.36 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $87.58 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $79.85 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $79.85 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.00 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.54 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $52.27 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.66 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.32 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 311 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 164 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 63 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 44 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 75 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 70 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
44 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
311 | 131 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
75 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1412 | 633 |
| Vascepa | Icosapent Ethyl | 1337 | 457 |
| Diclofenac Epolamine | Diclofenac Epolamine | 919 | 255 |
| Losartan Potassium | Losartan Potassium | 865 | 366 |
| Amlodipine Besylate | Amlodipine Besylate | 827 | 331 |
| Halobetasol Propionate | Halobetasol Propionate | 802 | 248 |
| Donepezil Hcl | Donepezil Hcl | 758 | 335 |
| Omeprazole | Omeprazole | 611 | 211 |
| Metformin Hcl | Metformin Hcl | 521 | 204 |
| Famotidine | Famotidine | 502 | 176 |
| Meclizine Hcl | Meclizine Hcl | 494 | 214 |
| Tamsulosin Hcl | Tamsulosin Hcl | 492 | 208 |
| Alendronate Sodium | Alendronate Sodium | 481 | 156 |
| Fluticasone Propionate | Fluticasone Propionate | 444 | 130 |
| Simvastatin | Simvastatin | 440 | 156 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 419 | 113 |
| Ammonium Lactate | Ammonium Lactate | 406 | 131 |
| Azithromycin | Azithromycin | 397 | 338 |
| Raloxifene Hcl | Raloxifene Hcl | 358 | 132 |
| Finasteride | Finasteride | 351 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 344 | 144 |
| Gabapentin | Gabapentin | 335 | 125 |
| Celecoxib | Celecoxib | 334 | 211 |
| Farxiga | Dapagliflozin Propanediol | 311 | 131 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 298 | 79 |
| Zolpidem Tartrate | Zolpidem Tartrate | 296 | 170 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 294 | 95 |
| Montelukast Sodium | Montelukast Sodium | 286 | 120 |
| Diclofenac Sodium | Diclofenac Sodium | 255 | 114 |
| Meloxicam | Meloxicam | 250 | 154 |
| Lisinopril | Lisinopril | 229 | 82 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 201 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 91 |
| Azelastine Hcl | Azelastine Hcl | 188 | 56 |
| Allopurinol | Allopurinol | 182 | 75 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 179 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 170 | 58 |
| Januvia | Sitagliptin Phosphate | 165 | 52 |
| Jardiance | Empagliflozin | 164 | 64 |
| Clotrimazole | Clotrimazole | 144 | 51 |
| Bepotastine Besilate | Bepotastine Besilate | 137 | 46 |
| Synthroid | Levothyroxine Sodium | 136 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 62 |
| Ezetimibe | Ezetimibe | 130 | 66 |
| Trazodone Hcl | Trazodone Hcl | 126 | 48 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 125 | 54 |
| Atenolol | Atenolol | 116 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 48 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 111 | 37 |
| Clobetasol Propionate | Clobetasol Propionate | 110 | 45 |
| Loperamide | Loperamide Hcl | 109 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 106 | 40 |
| Ketoconazole | Ketoconazole | 99 | 34 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 96 | 40 |
| Nebivolol Hcl | Nebivolol Hcl | 96 | 36 |
| Glipizide Er | Glipizide | 94 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 40 |
| Mometasone Furoate | Mometasone Furoate | 91 | 24 |
| Hydrocortisone | Hydrocortisone | 89 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 40 |
| Mupirocin | Mupirocin | 85 | 44 |
| Icosapent Ethyl | Icosapent Ethyl | 84 | 57 |
| Colchicine | Colchicine | 82 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 81 | 38 |
| Potassium Chloride | Potassium Chloride | 78 | 27 |
| Amoxicillin | Amoxicillin | 76 | 61 |
| Carvedilol | Carvedilol | 76 | 32 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 75 | 45 |
| Enalapril Maleate | Enalapril Maleate | 73 | 33 |
| Vemlidy | Tenofovir Alafenamide | 70 | 15 |
| Glyxambi | Empagliflozin/Linagliptin | 69 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 44 |
| Fenofibrate | Fenofibrate Nanocrystallized | 67 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 32 |
| Nexletol | Bempedoic Acid | 63 | 15 |
| Tradjenta | Linagliptin | 62 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 60 | 23 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 59 | 20 |
| Eliquis | Apixaban | 57 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 21 |
| Olanzapine | Olanzapine | 56 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 55 | 22 |
| Prednisone | Prednisone | 55 | 48 |
| Procto-Med Hc | Hydrocortisone | 55 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 20 |
| Xarelto | Rivaroxaban | 51 | 18 |
| Memantine Hcl | Memantine Hcl | 50 | 17 |
| Linzess | Linaclotide | 49 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 41 |
| Rybelsus | Semaglutide | 48 | 20 |
| Proctozone-Hc | Hydrocortisone | 47 | 22 |
| Fluocinonide | Fluocinonide | 45 | 24 |
| Fenofibrate | Fenofibrate,micronized | 44 | 19 |
| Prolia | Denosumab | 44 | 40 |
| Naproxen | Naproxen | 43 | 38 |
| Nifedipine Er | Nifedipine | 42 | 15 |
| Zenpep | Lipase/Protease/Amylase | 42 | 14 |
| Metformin Hcl Er | Metformin Hcl | 40 | 13 |
| Mirtazapine | Mirtazapine | 40 | 24 |
| Memantine Hcl Er | Memantine Hcl | 38 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 36 |
| Alcohol Pads | Alcohol Antiseptic Pads | 37 | 18 |
| Livalo | Pitavastatin Calcium | 36 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 12 |
| Dutasteride | Dutasteride | 35 | 15 |
| Furosemide | Furosemide | 35 | 20 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 34 | 12 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 34 | 13 |
| Glipizide | Glipizide | 33 | 12 |
| Ibuprofen | Ibuprofen | 33 | 14 |
| Lactulose | Lactulose | 33 | suppressed |
| Folic Acid | Folic Acid | 32 | 20 |
| Nitroglycerin | Nitroglycerin | 32 | 24 |
| Silver Sulfadiazine | Silver Sulfadiazine | 31 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 11 |
| Methimazole | Methimazole | 30 | 13 |
| Entecavir | Entecavir | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 14 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | 13 |
| Myrbetriq | Mirabegron | 27 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 25 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Benzonatate | Benzonatate | 23 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | 14 |
| Febuxostat | Febuxostat | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Ofloxacin | Ofloxacin | 22 | 18 |
| Ozempic | Semaglutide | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Acarbose | Acarbose | 21 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | 17 |
| Sucralfate | Sucralfate | 21 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 20 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Sf 5000 Plus | Fluoride (Sodium) | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | 13 |
| Silodosin | Silodosin | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Mupirocin | Mupirocin Calcium | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Topiramate | Topiramate | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,133.90 · 76 records | Gilead Sciences, Inc. | AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, JARDIANCE, NEXLETOL, OTEZLA, PROLIA, REPATHA, REXULTI, SHINGRIX, TEPEZZA, TRELEGY ELLIPTA, VOQUEZNA, Vemlidy, WELIREG, XIFAXAN, ZENPEP, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error